Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Dialysis01:27

Dialysis

231
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
231

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between food group intakes and metabolic acidosis in patients with non-dialysis-dependent chronic kidney disease.

BMC nephrology·2026
Same author

Centrifugation Selective Plasma Exchange: A Novel Hybrid Modality Combining Centrifugal Separation and Membrane-Based Plasma Fractionation.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·2026
Same author

Clinical Usefulness of Selective Plasma Exchange for Treating Pediatric Autoimmune Neurological Diseases.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·2026
Same author

Circulating Extracellular Vesicle MicroRNAs as Predictive Biomarkers for Kidney and Cardiovascular Events.

Journal of the American Heart Association·2025
Same author

Parathyroid Carcinoma in a Patient With End-Stage Renal Disease Initially Suspected With Refractory Secondary Hyperparathyroidism.

Cureus·2025
Same author

Association between serum bicarbonate and low mid-upper arm circumference in patients with non-dialysis-dependent chronic kidney disease: A cross-sectional study.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·2025

Related Experiment Video

Updated: May 13, 2025

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.4K

Rheocarna treatment for non-dialysis patients.

Atsushi Ohkubo1, Takatoshi Sakurasawa1, Yuki Hoshikawa1

  • 1Medical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.

Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
|April 14, 2025
PubMed
Summary

Rheocarna treatment for chronic limb ischemia in non-dialysis patients showed ulcer healing, though some required skin grafts. This study details treatment conditions and effectiveness in this patient group.

Keywords:
Rheocarnachronic lime‐threating ischemiafibrinogennon‐dialysis patientsvascular access

More Related Videos

Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

7.2K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.7K

Related Experiment Videos

Last Updated: May 13, 2025

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.4K
Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

7.2K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.7K

Area of Science:

  • Vascular Medicine
  • Regenerative Medicine

Background:

  • Rheocarna is an emerging therapy for chronic limb-threatening ischemia.
  • Previous studies focused on dialysis patients, leaving a gap in understanding its use in non-dialysis individuals.

Purpose of the Study:

  • To investigate the treatment conditions and efficacy of Rheocarna in non-dialysis patients with chronic limb-threatening ischemia.

Main Methods:

  • A case study of four non-dialysis patients receiving Rheocarna therapy.
  • Documentation of treatment parameters including duration, blood flow rate, and processed blood volume.

Main Results:

  • Complete ulcer healing was observed in all patients.
  • Two patients required subsequent skin grafting procedures.
  • Treatment involved 90-120 minutes, blood flow of 50-80 mL/min, and processed volume approximately 1.0 times circulating blood volume.
  • Low-density lipoprotein and fibrinogen removal rates were modest (10%-15%).

Conclusions:

  • Rheocarna can effectively promote ulcer healing in non-dialysis patients with chronic limb-threatening ischemia.
  • The study provides initial data on optimal treatment parameters for this population.
  • This is the first report detailing Rheocarna's application and outcomes in non-dialysis patients.